Lactate dehydrogenase contribution to symptom persistence in long COVID: A pooled analysis.

Autor: Udeh R; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, New South Wales, Australia., Utrero-Rico A; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Dolja-Gore X; School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia., Rahmati M; Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.; Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran., McEVoy M; School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.; La Trobe Rural Health School, College of Science, Health and Engineering, La Trobe University, Bendigo, VIC, Australia., Kenna T; Centre for Immunology & Infection Control, Queensland University of Technology, Bendigo, Queensland, Australia.
Jazyk: angličtina
Zdroj: Reviews in medical virology [Rev Med Virol] 2023 Nov; Vol. 33 (6), pp. e2477. Date of Electronic Publication: 2023 Sep 14.
DOI: 10.1002/rmv.2477
Abstrakt: There's critical need for risk predictors in long COVID. This meta-analysis evaluates the evidence for an association between plasma lactate dehydrogenase (LDH) and long COVID and explores the contribution of LDH to symptoms persistent across the distinct post-acute sequelae of COVID-19 (PASC) domains. PubMed, EMBASE, Web of Science, and Google Scholar were searched for articles published up to 20 March 2023 for studies that reported data on LDH levels in COVID-19 survivors with and without PASC. Random-effect meta-analysis was employed to estimate the standardized mean difference (SMD) with corresponding 95% confidence interval of each outcome. There were a total of 8289 study participants (3338 PASC vs. 4951 controls) from 46 studies. Our meta-analysis compared to the controls showed a significant association between LDH elevation and Resp-PASC [SMD = 1.07, 95%CI = 0.72, 1.41, p = 0.01] but not Cardio-PASC [SMD = 1.79, 95%CI = -0.02, 3.61, p = 0.05], Neuro-PASC [SMD = 0.19, 95%CI = -0.24, 0.61, p = 0.40], and Gastrointestinal-PASC [SMD = 0.45, 95%CI = -1.08, 1.98, p = 0.56]. This meta-analysis suggests elevated LDH can be used for predicting Resp-PASC, but not Cardio-PASC, Neuro-PASC or gastrointestinal-PASC. Thus, elevated plasma LDH following COVID infection may be considered as a disease biomarker.
(© 2023 The Authors. Reviews in Medical Virology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: